The Board of Directors (the “Board”) of iX Biopharma Ltd. (the “Company”), and together with its subsidiaries, the “Group”) wishes to announce that on 14 July 2026, the Company has allotted and issued 2,915,442 new ordinary shares, of which 1,004,036 new shares are allotted to Mr Albert Ho Shing Tung, a Director of the Company and 15,301 new shares to Centrum Capital Pte Ltd, a company in which Mr Ho is deemed to have an interest pursuant to the exercise of warrants at the exercise price of S$0.06 per warrant share. The number of issued shares of the Company has increased from 1,074,528,272 shares to 1,077,443,714 shares.

The new ordinary shares rank pari passu in all respects with the existing shares of the Company and are expected to be listed and quoted on the Singapore Exchange Securities Trading Limited on or around 16 July 2026. Pursuant to the aforesaid exercise of warrants, a cumulative total of 41,266,650 warrants, representing 71.76% of all warrants previously issued, have now been exercised and there are 16,242,829 outstanding warrants with an exercise price of S$0.06 for each warrant share.

Pursuant to the Warrant Conditions, the Warrants will expire on Friday, 17 July 2026 at 5.00 p.m., being the Market Day immediately preceding the second anniversary of the date of issue of the Warrants.

AFTER THE CLOSE OF BUSINESS AT 5.00 P.M. ON FRIDAY, 17 JULY 2026, ANY SUBSCRIPTION RIGHTS UNDER THE WARRANTS WHICH HAVE NOT BEEN EXERCISED WILL LAPSE AND EVERY WARRANT WILL THEREAFTER CEASE TO BE VALID FOR ANY PURPOSE WHATSOEVER.

Warrant holders may refer to the Company’s announcement on 16 June 2026 or https://www.ixbiopharma.com/warrants/ for instruction on how to exercise their warrants.